1. Medtech Insight
  2. >>Device Area

HHS Decision to End Free COVID-19 Testing Will Hurt Uninsured And Could Increase Infection Rates, Survey Finds

Nearly a quarter of test-takers have had out-of-pocket test costs

 
• By Brian Bossetta

Research from LendingTree finds the end to government coverage of COVID-19 tests for the uninsured will result in less testing and a potential spike in new cases.

FREE COVID TEST
• Source: Alamy

It seems after two long years there’s reason for optimism that the worst of the COVID-19 pandemic is over. New infection rates, hospitalizations, and deaths are declining, and the CDC says 91% of the country is within a “low-risk” area.

Still, health officials caution against letting our guard down as a new sub-variant of Omicron, BA.2, or “stealth Omicron” as it’s been dubbed, is spreading and is more transmissible than...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.